Lessons learned from using CDK 4/6 inhibitors to treat metastatic breast cancer I t is amazing to see how many new drugs are being developed and approved for patients with cancer. In 2015 alone, the US Food and Drug Administration approved 45 new cancer drugs -a signi cant jump from the average 26 approvals annually from 2006 to 2014. is major shift in the number of approvals is due to many factors, including the intensi ed e orts by scientists and clinicians to develop new drugs, especially novel immunotherapies, and changes in the FDA's drug approval process under the leadership of Dr Richard Pazdur.
As immunotherapies rede ne the broader cancer treatment paradigm, in breast cancer, CDK 4/6 inhibitors are quietly revolutionizing treatment options for estrogen-receptor-positive metastatic disease. ree exciting drugs -palbociclib, abemaciclib, and ribociclib are in various stages of development.
In February 2015, the agency approved palbociclib in combination with letrozole for treatment of rst-line ER-positive metastatic breast cancer, based on results from the PALOMA II trial, which showed a doubling of progression-free survival with the combination. 1 So far, no drug has shown such an improvement in progression-free survival in hormone-receptor-positive metastatic breast cancer. A year later, in March 2016, the agency approved the combination of palbocicilb with fulvestrant based on PALOMA III results 2 as a second-line therapy in women with HR-positive, HER2-negative metastatic breast cancer.
In October 2015, another CDK 4/6 inhibitor, abemaciclib, received Breakthrough erapy Designation from the FDA for use in patients with refractory HR-positive advanced or metastatic breast cancer. Data from the breast cancer cohort expansion of the phase 1 JPBA trial formed the basis of the designation. 3 e trial focused on the ecacy and safety of abemaciclib in women with advanced or metastatic breast cancer who had received a median of 7 previous systemic treatments. Even in heavily pretreated patients, abemaciclib showed activity as a single agent.
Most recently, in August 2016, the agency gave another breakthrough designation to ribociclib, or LEE011, as a rst-line treatment for HR-positive, HER2-negative, advanced breast cancer based on ndings in the phase 3 MONALEESA-2 trial in which ribociclib in combination with letrozole in postmenopausal women who had received no previous therapy for their advanced disease.
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Cellular proliferation, mediated by dysregulation of the cell cycle and activation of cyclin-dependent kinases (CDKs) to enhance cell-cycle progression, is the cornerstone of cancer progression. e new generation of selective CDK 4/6 inhibitors, including palbociclib, abemaciclib, and ribociclib, have shown that the inhibitors have an important role in the G1-to-S-phase cell-cycle transition, showing improved e ectiveness with fewer adverse e ects.
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e most common side e ects are neutropenia, leukopenia, and fatigue. It is worth noting that the incidence of fever neutropenia is extremely rare (less than 2%).
Unlike with palbociclib and ribociclib, fatigue was the dose-limiting toxicity of abemaciclib. e side e ects for abemaciclib included fatigue (all grades, 41%; grade 3, 3%), diarrhea (63% and 5%, respectively), nausea (45% and 2%), vomiting (25% and 1%), and anorexia (17% and none). Diarrhea was common but manageable with antidiarrheal agents or dose reduction. Hematologic side e ects for abemaciclib were less common than they were for palbociclib and ribociclib.
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I have learned a number of lessons by using CDK 4/6 inhibitors. Based on data and our experience with patients with metastatic receptor-positive breast cancer, even if they have visceral disease, we can safely start them on the palbociclib-letrozole combination. is will spare a large number of patients from the side e ects of chemotherapy. is is a paradigm shift in our decision making. I have also learned that we have to be very patient with palbociclib. We are not going to see a major response right away. We will see reduction in the tumor size, but it may not be as much as we might see with other targeted therapies or chemotherapy agents. We will also see large number of patients achieve stable disease, and a large number of partial responses. As such, we have to educate our patients about the importance of staying on the treatment.
As far as side e ects are concerned, we will see a reduction in white blood cells and neutrophils. Follow the pack-age insert for dose modi cations. But even with low whitecell counts, patients will do ne and they are not going to get an infection. e incidence of neutropenic fever with palbociclib is very rare (less than 2%). It took some time for me to get comfortable with this and to not stop, delay, or dose reduce for uncomplicated neutropenia.
Data from all CDK 4/6 inhibitors are very promising, and these agents will o er highly viable options for our patients with metastatic breast cancer. Looking forward, ongoing studies are now examining the role of palbociclib in earlystage breast cancer (PENELOPE-B, NCT01864746; and PALLAS, NCT02513394).
